Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next
Author: TMFTwitty Big funky green star, 20000 posts Old School Fool CAPS All Star Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 111  
Subject: Try Again, Trimeris Date: 1/7/2004 4:35 PM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 0
http://www.fool.com/News/mft/2004/mft04010703.htm?ref=btp

Try Again, Trimeris

By Alyce Lomax
January 7, 2004

Headline skimmers, beware. When a company plays "hide and seek," and the object that's hiding is a piece of bad news, it's no laughing matter to investors. Trimeris (Nasdaq: TRMS) got busted Monday following market close after it issued what was considered a rather deceptive press release. Its stock took a 14.5% hit Tuesday, and analysts scrutinized the company, accusing it of burying bad news.

The whole brouhaha started Monday evening, when Trimeris issued a press release with the headline, "Following the Successful Development of FUZEON, Roche and Trimeris Sign Research Agreement to Develop Next Generation of HIV Infusion Inhibitors."

Three paragraphs into the announcement, in the last line, is the following statement at the crux of the issue: "Due to challenges in achieving the desired technical profile of the current formulation of the investigational compound T-1249, Roche and Trimeris have decided to put the early stage clinical program of T-1249 on hold."

Many investors didn't miss a note, though, as the stock began plummeting in after-hours trading that night. In addition, a reporter pulled the information, despite a headline that looked like a fairly commonplace press announcement.

According to Reuters Tuesday, the company denied analysts' claims that it had buried anything. You know -- the old, "Hey, it's right there" routine -- and, after all, it is. In adherence with the SEC's Regulation FD, the same press release is filed as an exhibit to a Form 8-K.

We all know that press releases can be confusing, given the usual spin administered by corporate public relations departments, but this story underlines the importance of doing more than a headline and two-paragraph skim. Foolish investors know that careful scrutiny can make a difference in a situation like this one.

The stock dropped about 14.5% in Tuesday's trading session, and it continued to fall today. It's no surprise if investors feel their trust shaken, and the prognosis might not be so rosy seeing how T-1249 is the only drug Trimeris had in clinical trials right now. Investors have little reason to hide their displeasure on this one.

Alyce Lomax welcomes your feedback at alomax@fool.com.
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next

Announcements

Managing Your Wealth
Our own TMFHockeypop from Rule Your Retirement fame on the TV show Managing Your Wealth.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Post of the Day:
Apple

Apple and Ninety Years Ago
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement